HPHA Stock Overview
Heidelberg Pharma AG, a biopharmaceutical company, focuses on oncology and antibody targeted amanitin conjugates (ATAC) in Germany, other European countries, the United States, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Heidelberg Pharma AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €3.04 |
| 52 Week High | €4.09 |
| 52 Week Low | €2.63 |
| Beta | -0.31 |
| 1 Month Change | -0.33% |
| 3 Month Change | -6.17% |
| 1 Year Change | -24.75% |
| 3 Year Change | -59.68% |
| 5 Year Change | -2.56% |
| Change since IPO | -94.25% |
Recent News & Updates
Is Heidelberg Pharma (ETR:HPHA) A Risky Investment?
Feb 16
Heidelberg Pharma AG's (ETR:HPHA) Price In Tune With Revenues
Dec 05Recent updates
Is Heidelberg Pharma (ETR:HPHA) A Risky Investment?
Feb 16Heidelberg Pharma AG's (ETR:HPHA) Price In Tune With Revenues
Dec 05Industry Analysts Just Upgraded Their Heidelberg Pharma AG (ETR:HPHA) Revenue Forecasts By 21%
Jul 21Analyst Forecasts For Heidelberg Pharma AG (ETR:HPHA) Are Surging Higher
Oct 16Heidelberg Pharma (ETR:HPHA) Will Have To Spend Its Cash Wisely
Nov 28Heidelberg Pharma AG (ETR:HPHA) Analysts Are More Bearish Than They Used To Be
Mar 27We Think Heidelberg Pharma (ETR:HPHA) Needs To Drive Business Growth Carefully
Mar 15Investors Who Bought Heidelberg Pharma (ETR:HPHA) Shares Five Years Ago Are Now Up 245%
Jan 17
We Think Heidelberg Pharma (ETR:HPHA) Needs To Drive Business Growth Carefully
Dec 14Shareholder Returns
| HPHA | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 2.7% | -1.2% | 1.7% |
| 1Y | -24.8% | -23.0% | 2.3% |
Return vs Industry: HPHA underperformed the German Biotechs industry which returned -23% over the past year.
Return vs Market: HPHA underperformed the German Market which returned 2.3% over the past year.
Price Volatility
| HPHA volatility | |
|---|---|
| HPHA Average Weekly Movement | 3.8% |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.1% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: HPHA has not had significant price volatility in the past 3 months.
Volatility Over Time: HPHA's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 95 | Andreas Pahl | heidelberg-pharma.com |
Heidelberg Pharma AG, a biopharmaceutical company, focuses on oncology and antibody targeted amanitin conjugates (ATAC) in Germany, other European countries, the United States, and internationally. Its lead product candidate is HDP-101, which in the Phase I/IIa study for the treatment of relapsed or refractory multiple myeloma. The company is developing HDP-102 for the treatment of non-Hodgkin lymphoma; HDP-103, an ATAC candidate to treat metastatic castration-resistant prostate cancer; HDP-104 for the treatment of gastrointestinal tumors.
Heidelberg Pharma AG Fundamentals Summary
| HPHA fundamental statistics | |
|---|---|
| Market cap | €141.68m |
| Earnings (TTM) | -€20.35m |
| Revenue (TTM) | €9.86m |
14.4x
P/S Ratio-7.0x
P/E RatioIs HPHA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HPHA income statement (TTM) | |
|---|---|
| Revenue | €9.86m |
| Cost of Revenue | €3.25m |
| Gross Profit | €6.61m |
| Other Expenses | €26.95m |
| Earnings | -€20.35m |
Last Reported Earnings
Nov 30, 2023
Next Earnings Date
Jul 11, 2024
| Earnings per share (EPS) | -0.44 |
| Gross Margin | 67.01% |
| Net Profit Margin | -206.38% |
| Debt/Equity Ratio | 11.4% |
How did HPHA perform over the long term?
See historical performance and comparison